参考来源: Martin Zarba, et al.Systemic treatments in favorable and very favorable risk metastatic renal cell carcinoma (mRCC): Real world evidence from the International mRCC Database Consortium (IMDC).J Clin Oncol 42, 202...
Official website of the International mRCC Database Consortium (IMDC), including an up-to-date IMDC Prognosis Risk Calculator (IMDC Criteria / Heng Criteria) in addition to all past and present research fellows, publications, presentations and partici
Overall, patients who improved their IMDC risk score reached better survival outcomes than those who remained stable/deteriorated. In our sub-analysis, the shift in the IMDC risk category appears to be a helpful prognostic tool for assessing the outcomes of patients with mRCC...
摘要号:LBA8 标题:Phase III study of cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in previously untreated advanced renal cell carcinoma (aRCC) of IMDC intermediate or poor risk (COSMIC-313...
We want you to love being in "The Business" of making great films. THIS IS A HIGH-RISK INVESTMENTWe strongly believe we will succeed, but we can make no guarantees. God can have other plans! Do not invest money which would cause you serious financial problems if it were gone....
第9期 李明敏 ,等 .基于总体死亡风险构建优化减瘤性肾切除术患者选择的IMDC-Olig 模型· 659 · 基于模型公式计算 IMDC-Olig 危险评分: Riskscore=0.8912(ifIMDCintermediaterisk)+ 1.4545(ifIMDChighrisk)+0.8277(ifnotoligo- metastasis),为了方便临床应用通过半定量 赋值整数转换 ,Riskscore=1(ifIMDCintermediate...
was 46%, higher with IO-TKI than with IO-IO [71% vs 29%, OR 0.70 (0.21-1.56); p=0.38].Conclusions:These preliminary analyses of the ongoing Meet-URO 33 study show no clear survival advantage in using an IO-TKI combinations instead of an IO-IO combination in IMDC poor-risk patients...
In regression analysis, the survival results in the good IMDC risk group were superior to those in the intermediate/poor IMDC group (hazard ratio for death 0.27, 95% CI: 0.08-0.92; p=0.037; hazard ratio for progression 0.33, 95% CI: 0.11-0.96; p=0.042). Conclusions The combination of ...
Martin Zarba, et al.Systemic treatments in favorable and very favorable risk metastatic renal cell carcinoma (mRCC): Real world evidence from the International mRCC Database Consortium (IMDC).J Clin Oncol 42, 2024 (suppl 16; abstr 4514) ...
Patients who received first-line TT with an intermediate or poor risk disease and whose diagnosis to treatment interval was less than 1 year, similar to those enrolled inPhase 3 Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma(ADAPT...